Düsseldorf || 16 - 19 November 2026

Jubaan

Gixam, a non-invasive, AI imaging platform to detect Gastrointestinal disorders and colorectal adenomas for CRC

Therapeutic areas: · ·
Company status: Early Revenue
Company profile

Solution at a glance

Jubaan is developing a non-invasive, AI imaging platform to detect GI (Gastro Intestinal) disorders based on deep learning of images taken from the human tongue. The platform is based on mappings of microbiome using spectral imaging and aiming to replace the FOBT/FIT (Fecal Occult Blood Test). By utilizing cutting-edge Artificial Intelligence and Deep Learning technologies, Jubaan is set to become a game-changer for early detection of GI disorders, saving the healthcare industry valuable resources and most importantly saving lives by providing better and expedient patient outcomes.
Meet us at MEDICA 2026

David Rainis

CEO
Düsseldorf · 16 – 19 November 2026 · Israel Pavilion

Ready to expand globally?